Citadel Advisors
CTSO icon

Citadel Advisors’s Cytosorbents Corp CTSO Stock Holding History

Citadel Advisors’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.39K Buy
+14,400
New +$7.61K ﹤0.01% 13535
2025
Q3 		– Sell
-28,900
Closed -$37K – 12947
2025
Q2 		$37K Buy
28,900
+20,800
+257% +$20.9K ﹤0.01% 11908
2025
Q1 		$8.1K Sell
8,100
-7,900
-49% -$8.32K ﹤0.01% 13661
2024
Q4 		$14.6K Buy
16,000
+600
+4% +$589 ﹤0.01% 13401
2024
Q3 		$23.1K Buy
15,400
+5,300
+52% +$5.81K ﹤0.01% 12671
2024
Q2 		$7.1K Buy
+10,100
New +$8.76K ﹤0.01% 13279
2023
Q4 		– Sell
-2,200
Closed -$4.14K – 14382
2023
Q3 		$4.14K Sell
2,200
-13,900
-86% -$39.9K ﹤0.01% 13514
2023
Q2 		$57.8K Buy
16,100
+900
+6% +$2.85K ﹤0.01% 11633
2023
Q1 		$51.2K Buy
+15,200
New +$45.6K ﹤0.01% 12110
2021
Q3 		– Sell
-27,500
Closed -$208K – 13889
2021
Q2 		$208K Buy
27,500
+9,300
+51% +$78.4K ﹤0.01% 12065
2021
Q1 		$158K Buy
18,200
+4,500
+33% +$42.9K ﹤0.01% 11978
2020
Q4 		$109K Sell
13,700
-18,900
-58% -$158K ﹤0.01% 10172
2020
Q3 		$260K Sell
32,600
-16,200
-33% -$146K ﹤0.01% 8381
2020
Q2 		$483K Buy
48,800
+15,500
+47% +$142K ﹤0.01% 7140
2020
Q1 		$257K Buy
+33,300
New +$168K ﹤0.01% 7584
2019
Q1 		– Sell
-11,900
Closed -$96K – 9335
2018
Q4 		$96K Buy
+11,900
New +$118K ﹤0.01% 8258
2018
Q3 		– Sell
-25,700
Closed -$293K – 9264
2018
Q2 		$293K Buy
25,700
+13,000
+102% +$123K ﹤0.01% 7249
2018
Q1 		$90K Buy
12,700
+1,000
+9% +$7.56K ﹤0.01% 7745
2017
Q4 		$76K Sell
11,700
-3,200
-21% -$20.4K ﹤0.01% 7510
2017
Q3 		$92K Buy
+14,900
New +$75.9K ﹤0.01% 7061
2016
Q2 		– Sell
-13,700
Closed -$54K – 6891
2016
Q1 		$54K Buy
+13,700
New +$59.4K ﹤0.01% 6232
2015
Q4 		– Sell
-600
Closed -$4K – 8774
2015
Q3 		$4K Sell
600
-6,500
-92% -$43.4K ﹤0.01% 8661
2015
Q2 		$44K Buy
+7,100
New +$48.3K ﹤0.01% 7730

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors's CTSO Position: Q2 2026 in Review

Citadel Advisors sold out of Cytosorbents Corp (CTSO) in Q2 2026, closing a stake of 10,799 shares — an estimated $5.7K sold.

Citadel Advisors first reported a position in CTSO in Q2 2015 and held it in 24 quarters. The position peaked at $1.03M in Q3 2020. 51 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.

  • Citadel Advisors reported no remaining Cytosorbents Corp position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 10,799 Cytosorbents Corp shares in Q2 2026, an estimated $5.7K.
  • Citadel Advisors first reported a position in Cytosorbents Corp in Q2 2015 and held it in 24 quarters.
  • Citadel Advisors's Cytosorbents Corp position peaked at $1.03M in Q3 2020.
  • 51 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.